Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer

por Bottini, A, Berruti, A, Brizzi, M P, Bersiga, A, Generali, D, Allevi, G, Aguggini, S, Bolsi, G, Bonardi, S, Bertoli, G, Alquati, P, Dogliotti, L
Publicado 2003

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

por Bottini, A, Berruti, A, Bersiga, A, Brizzi, M P, Bruzzi, P, Aguggini, S, Brunelli, A, Bolsi, G, Allevi, G, Generali, D, Betri, E, Bertoli, G, Alquati, P, Dogliotti, L
Publicado 2001

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

por Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A
Publicado 2008

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri...

por Fox, Stephen B, Generali, Daniele, Berruti, Alfredo, Brizzi, Maria P, Campo, Leticia, Bonardi, Simone, Bersiga, Alessandra, Allevi, Giovanni, Milani, Manuela, Aguggini, Sergio, Mele, Teresa, Dogliotti, Luigi, Bottini, Alberto, Harris, Adrian L
Publicado 2011

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado 2013

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer

por Milani, Manuela, Venturini, Sergio, Bonardi, Simone, Allevi, Giovanni, Strina, Carla, Cappelletti, Maria Rosa, Corona, Silvia Paola, Aguggini, Sergio, Bottini, Alberto, Berruti, Alfredo, Jubb, Adrian, Campo, Leticia, Harris, Adrian L., Gatter, Kevin, Fox, Stephen B., Generali, Daniele, Roviello, Giandomenico
Publicado 2017

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib

por Schettini, Francesco, De Bonis, Maria Valeria, Strina, Carla, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Ciliberto, Ignazio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ungari, Marco, Locci, Mariavittoria, Paris, Ida, Scambia, Giovanni, Ruocco, Gianpaolo, Generali, Daniele
Publicado 2023

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado 2015

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial

por Schettini, Francesco, Corona, Silvia Paola, Giudici, Fabiola, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Molteni, Alfredo, Lazzari, Maria Chiara, Ferrero, Giuseppina, Ungari, Marco, Marasco, Elena, Bruson, Alice, Xumerle, Luciano, Zago, Elisa, Cerra, Davide, Loddo, Marco, Williams, Gareth H., Paris, Ida, Scambia, Giovanni, Generali, Daniele
Publicado 2021